Ignite Creation Date:
2024-05-06 @ 2:02 PM
Last Modification Date:
2024-10-26 @ 1:24 PM
Study NCT ID:
NCT04197986
Status:
TERMINATED
Last Update Posted:
2024-03-13
First Post:
2019-12-02
Brief Title:
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
Sponsor:
QED Therapeutics Inc
Organization:
QED Therapeutics Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Urothelial Bladder Cancer |
| Upper Tract Urothelial Carcinomas |
Keywords:
| Name | View |
|---|---|
| Cystectomy | View |
| FGFR3 Genetic Alterations | View |
| Upper Tract Urothelial Carcinomas | View |
| UTUC | View |
| Muscle Invasive Urothelial Carcinoma | View |
| Fibroblast Growth Factor Receptor Inhibitor | View |
| BGJ398 | View |
| FGFR3 | View |
| Urothelial Bladder Cancer | View |
| UBC | View |
| Infigratinib Phosphate | View |
| Infigratinib | View |
| Adjuvant | View |
| Nephroureterectomy | View |
| Distal ureterectomy | View |